摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[(6S,7R,8R,12S,19S,26S)-26-(2-amino-2-oxoethyl)-8-hydroxy-19-[(R)-hydroxy(phenyl)methyl]-12-[(4-hydroxyphenyl)methyl]-7,23-dimethyl-11,14,21,28-tetraoxo-4,17,24,31,41-pentathia-10,13,20,27,37,42,43,44,45,46-decazaoctacyclo[37.2.1.12,5.115,18.122,25.129,32.06,10.033,38]hexatetraconta-1(42),2,5(46),15,18(45),22,25(44),29,32(43),33(38),34,36,39-tridecaen-36-yl]-1,3-thiazole-4-carboxylic acid | 1092397-37-9

中文名称
——
中文别名
——
英文名称
2-[(6S,7R,8R,12S,19S,26S)-26-(2-amino-2-oxoethyl)-8-hydroxy-19-[(R)-hydroxy(phenyl)methyl]-12-[(4-hydroxyphenyl)methyl]-7,23-dimethyl-11,14,21,28-tetraoxo-4,17,24,31,41-pentathia-10,13,20,27,37,42,43,44,45,46-decazaoctacyclo[37.2.1.12,5.115,18.122,25.129,32.06,10.033,38]hexatetraconta-1(42),2,5(46),15,18(45),22,25(44),29,32(43),33(38),34,36,39-tridecaen-36-yl]-1,3-thiazole-4-carboxylic acid
英文别名
——
2-[(6S,7R,8R,12S,19S,26S)-26-(2-amino-2-oxoethyl)-8-hydroxy-19-[(R)-hydroxy(phenyl)methyl]-12-[(4-hydroxyphenyl)methyl]-7,23-dimethyl-11,14,21,28-tetraoxo-4,17,24,31,41-pentathia-10,13,20,27,37,42,43,44,45,46-decazaoctacyclo[37.2.1.12,5.115,18.122,25.129,32.06,10.033,38]hexatetraconta-1(42),2,5(46),15,18(45),22,25(44),29,32(43),33(38),34,36,39-tridecaen-36-yl]-1,3-thiazole-4-carboxylic acid化学式
CAS
1092397-37-9
化学式
C53H44N12O10S6
mdl
——
分子量
1201.4
InChiKey
JZHFCZZBFHASDW-VAGMZVTLSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.5
  • 重原子数:
    81
  • 可旋转键数:
    8
  • 环数:
    11.0
  • sp3杂化的碳原子比例:
    0.23
  • 拓扑面积:
    508
  • 氢给体数:
    8
  • 氢受体数:
    23

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • MACROCYCLES AND THEIR USES
    申请人:Fujimoto Roger Aki
    公开号:US20090186830A1
    公开(公告)日:2009-07-23
    The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases.
    本申请描述了对治疗、预防和/或改善疾病有用的有机化合物。
  • Macrocycles and Their Uses
    申请人:Novartis AG
    公开号:US20130252883A1
    公开(公告)日:2013-09-26
    The present application describes a method of treating a bacterial infection comprising administering to a subject in need thereof a pharmaceutically acceptable amount of a defined macrocycle compound.
    本申请描述了一种治疗细菌感染的方法,包括向需要治疗的对象施用一定量的定义的大环化合物的药学可接受量。
  • US8476224B2
    申请人:——
    公开号:US8476224B2
    公开(公告)日:2013-07-02
  • Antibacterial and Solubility Optimization of Thiomuracin A
    作者:Matthew J. LaMarche、Jennifer A. Leeds、Jason Brewer、Karl Dean、Jian Ding、Joanne Dzink-Fox、Gabe Gamber、Akash Jain、Ryan Kerrigan、Philipp Krastel、Kwangho Lee、Franco Lombardo、David McKenney、Georg Neckermann、Colin Osborne、Deborah Palestrant、Michael A. Patane、Elin M. Rann、Zachary Robinson、Esther Schmitt、Travis Stams、Stacey Tiamfook、Donghui Yu、Lewis Whitehead
    DOI:10.1021/acs.jmedchem.6b00726
    日期:2016.7.28
    Synthetic studies of the antimicrobial secondary metabolite thiomuracin A (1) provided access to analogues in the Northern region (C2-C10). Selective hydrolysis of the C10 amide of lead compound 2 and subsequent derivatization led to novel carbon -and nitrogen-linked analogues (e.g., 3) which improved antibacterial potency across a panel of Gram-positive organisms. In addition, congeners with improved physicochemical properties were identified which proved efficacious in murine sepsis and hamster C. difficile models of disease. Optimal efficacy in the hamster model of C. difficile was achieved with compounds that possessed both potent antibacterial activity and high aqueous solubility.
查看更多